Most Read Articles
06 Jul 2020
Routinely used for treating cardiovascular diseases, statins have been shown to benefit other conditions, and new evidence suggests that using the drug at high intensity reduces the risk of hip or knee replacement, an effect that may be specific to rheumatoid arthritis.
Jairia Dela Cruz, 06 Jul 2020
Following vegan and vegetarian diets, which offer plenty of what is good for health, has been reported to have a downside: an increased risk of depression and anxiety, especially for younger adults.
Pearl Toh, 29 Jun 2020
Having migraine during midlife appears to be associated with a higher risk of developing dementia in later life, according to a large population-based longitudinal Danish study presented at the AHS* 2020 Virtual Meeting, indicating that migraine may be a risk factor for dementia.
Roshini Claire Anthony, 5 days ago

Upadacitinib may be a suitable treatment for patients with active psoriatic arthritis (PsA) who have insufficient response to non-biologic disease-modifying anti-rheumatic drugs (non-bDMARDs), according to results of the phase III SELECT-PsA-1* trial presented at EULAR 2020.

Delayed adverse events uncommon after injection with hyaluronic acid fillers

18 Jun 2020

Delayed adverse events (DAEs) associated with hyaluronic acid fillers (HA-Vs) appear to be relatively rare, a new study reports.

The researchers conducted a long-term retrospective analysis of 9,324 HA-V treatments in 4,500 patients. Over 9 years of chart follow-up, 44 patients (aged 27–79 years; 34 women) experienced DAEs. Overall, a cumulative of 19,498.5 mL of fillers was administered. Those who developed DAEs received 0.5–13.3 mL of HA-V in multiple locations.

The resulting combined incidence rates of DAEs were 0.98 percent per patient, 0.47 percent per treatment, and 0.23 percent per 1-mL syringe. The most common sites of injection were at the mid- and lower face. Almost half of the participants were given more than one HA-V treatment before DAEs developed.

The median time to DAE onset from the most recent HA-V injection was 4 months. Delayed swelling and nodule formation were the most common AEs, each recorded in 29 patients. Other frequent side effects included erythema, warmth, tenderness, and pain. Two patients experienced DAEs with more than one episode.

Notably, all cases of DAEs were resolved, with six patients requiring no treatment. The most common treatment was oral prednisone (58 percent). Other modalities included hyaluronidase (45.4 percent), oral antibiotics (41.0 percent), and intralesional triamcinolone acetonide (34.1 percent).

“Patients who experienced DAEs received a larger cumulative amount of HA-V than those who did not,” researchers said. “Further investigation of possible contributing factors will give clinicians a clearer idea of the relationship, if any, between volume and DAE risk.”

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
06 Jul 2020
Routinely used for treating cardiovascular diseases, statins have been shown to benefit other conditions, and new evidence suggests that using the drug at high intensity reduces the risk of hip or knee replacement, an effect that may be specific to rheumatoid arthritis.
Jairia Dela Cruz, 06 Jul 2020
Following vegan and vegetarian diets, which offer plenty of what is good for health, has been reported to have a downside: an increased risk of depression and anxiety, especially for younger adults.
Pearl Toh, 29 Jun 2020
Having migraine during midlife appears to be associated with a higher risk of developing dementia in later life, according to a large population-based longitudinal Danish study presented at the AHS* 2020 Virtual Meeting, indicating that migraine may be a risk factor for dementia.
Roshini Claire Anthony, 5 days ago

Upadacitinib may be a suitable treatment for patients with active psoriatic arthritis (PsA) who have insufficient response to non-biologic disease-modifying anti-rheumatic drugs (non-bDMARDs), according to results of the phase III SELECT-PsA-1* trial presented at EULAR 2020.